Richard Marshall
Patrimonio netto: 22 417 $ in data 31/05/2026
Patrimonio netto: 22 417 $ in data 31/05/2026
Richard Marshall is Chief Executive Officer at Juvenescence Ltd. and Juvenescence Therapeutics Ltd. since 2023.
Since 2024, Dr. Marshall is an Independent Director at Serina Therapeutics, Inc. From 2019 to 2023, Dr. Marshall was SVP, Global Head-Respiratory & Immunology at AstraZeneca PLC.
From 2002 to 2018, Dr. Marshall was Vice President-Fibrosis Research & Development at GSK Plc.
Dr. Marshall completed undergraduate and doctorate degrees at University College London.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
0,08% | 17/06/2026 | 12.183 ( 0,08% ) | 22 417 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Amministratore Delegato | 16/01/2023 |
| Società | Posizione | Fine |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2023 |
| GSK PLC | Corporate Officer/Principal | 01/01/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale